Clearside Biomedical, Inc.
CLSDQ Healthcare Biotechnology
Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.
Follow CLSDQ
Clearside Biomedical, Inc. (CLSDQ) EV/Sales
As of 22 July 2026, Clearside Biomedical, Inc. (CLSDQ) trades at a EV/Sales of −1.2×. Over the past ten years it has ranged from −57.4× (December 2018) to 9,005× (June 2017); the current reading is higher than 2% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 31.0× | 387.52% |
| FY2023 | 6.3× | (68.00%) |
| FY2022 | 19.8× | 344.89% |
| FY2021 | 4.5× | (68.45%) |
| FY2020 | 14.1× | (67.08%) |
| FY2019 | 42.9× | 640.89% |
| FY2018 | 5.8× | (98.69%) |
| FY2017 | 442× | 366.41% |
| FY2016 | 94.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 4.6× | (64.62%) |
| Jun 2025 | 13.0× | (15.98%) |
| Mar 2025 | 15.5× | (49.87%) |
| Dec 2024 | 31.0× | 227.91% |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRTX Biorestorative Therapies, Inc. compare | −5.7× |
| CLSDQ Clearside Biomedical, Inc. | −1.2× |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | 0.0× |
| OGEN Oragenics, Inc. compare | 3.6× |
| WINT Windtree Therapeutics, Inc. compare | 63.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)